Home
About Us
Duoribio
Corporate Philosophy
Development History
Core Advantages
Core Products
Lanreotide Acetate
Tirzepatide(under development)
Semaglutide(under development)
Retatrutide(under development)
Pegcetacoplan(under development)
Albuvirtide(under development)
CDMO Service
Development Phase
Technology Transfer
Process Validation
Registration Declaration
Join Us
Talent Concept
Recruitment Information
News Center
Company News
Technical Disclosure
Contact Us
中文
Retatrutide(under development)
四川多瑞药业
2025-05-22
Feature: Three-target GLP-1R/GCGR/GIPR
Status: Under development
Prev：
Semaglutide(under development)
Next：
Pegcetacoplan(under development)